Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | CASP6 | P55212 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884641 | 0.89 | MEN1 (0.62) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL9358156 | 0.89 | ALDH1A1 (0.64) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL725608 | 0.87 | NR1H3 (0.67) | ALDH1A1MEN1KMT2AMGLLNR1H3 | |
| SCHEMBL17946142 | 0.85 | ALDH1A1 (0.60) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL726842 | 0.85 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL11616740 | 0.83 | MEN1 (0.70) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL11649332 | 0.83 | MGLL (0.64) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL6581387 | 0.83 | ALDH1A1 (0.59) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL17326723 | 0.83 | KDM4E (0.57) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 | |
| SCHEMBL28378925 | 0.82 | CASP6 (0.52) | KDM4EALDH1A1SMN1; SMN2CASP6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466799-B | N-substituted phthalic acid diamide preparation method of imine compound | 西北师范大学 | 2024-12-24 | — | — | CN | disclosed |
| CN-117466799-A | Preparation method of N-substituted phthalimide compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| WO-2011121062-A1 | COMPOSITION FOR THE TREATMENT OF PERIODONTITIS AND OTHER INFLAMMATORY INFECTIOUS DISEASES | VOCKNER HELMUT (AT) | 2011-10-06 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| CN-100537032-C | Phosphazenium salt phase transfer catalysts | GEN ELECTRIC (NL) | 2009-09-09 | — | — | CN | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| CN-101125300-A | Phosphazenium salt phase transfer catalysts | GEN ELECTRIC (US) | 2008-02-20 | — | — | CN | disclosed |
| US-4054654-A | ANTIARRHYTHMIA AGENTS | RHONE-POULENC, S.A. (FR) | 1977-10-18 | — | — | US | disclosed |
| US-3987174-A | ANTIARRHYTHMIA AGENTS | RHONE-POULENC S.A. (FR) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | KDM4E 2606/4885ALDH1A1 4339/4885SMN1; SMN2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.